Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Seres Therapeutics, Inc. (MCRB)
Last seres therapeutics, inc. earnings: 11/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.serestherapeutics.com
Company Research
Source: GlobeNewswire
Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) at day 30 post-HSCT; Company expects to submit draft study protocol to FDA in Q2 2025 SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, are consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support potential for live biotherapeutics to address inflammatory and immune diseases Company advances SER-155 strategic partnership discussions to accelerate next study in allo-HSCT and support potential expansion into other target populations With current cash, expected second installment payment from Nestlé, and based on current operating plans, Seres expects to fund operations into Q1 2026 Conference call at 8:30 a.m. ET today CAMBRI
Show less
Read more
Impact Snapshot
Event Time:
MCRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MCRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MCRB alerts
High impacting Seres Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MCRB
News
- Seres Therapeutics to Participate in Piper Sandler Healthcare ConferenceGlobeNewswire
- Seres Therapeutics (NASDAQ:MCRB) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswire
- Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025GlobeNewswire
- Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155GlobeNewswire
MCRB
Earnings
- 11/5/25 - Beat
MCRB
Analyst Actions
- 9/24/25 - Canaccord Genuity
MCRB
Sec Filings
- 11/18/25 - Form 4
- 11/18/25 - Form 4
- 11/18/25 - Form 4
- MCRB's page on the SEC website